INmune Bio reported significant progress in the third quarter of 2025, highlighted by advancements in its CORDStrom and XPro platforms, alongside an accelerated development pipeline aimed at addressing unmet medical needs.

• Preparing for regulatory submissions for CORDStrom in the U.K. and U.S. targeting recessive dystrophic epidermolysis bullosa (RDEB).
• Positive interim results from the Phase II MINDFuL trial for XPro in Alzheimer's disease, indicating potential efficacy linked to baseline inflammation levels.
• Completion of the INKmune Phase II trial in prostate cancer ahead of schedule, with key endpoints met.
• A multi-platform strategy demonstrating viability with two late-stage therapeutics advancing in development.
• Anticipation of pivotal 2026 milestones, including regulatory discussions and potential market approvals.